{
  "cik": 1658551,
  "cik_padded": "0001658551",
  "entityName": "Amylyx Pharmaceuticals, Inc.",
  "fiscal_years": [
    {
      "accn": "0001193125-26-086645",
      "filed": "2026-03-03",
      "fiscal_year": 2025,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 138000.0,
        "cash": 226651000.0,
        "eps_diluted": -1.53,
        "free_cash_flow": -123481000.0,
        "net_income": -144735000.0,
        "operating_cash_flow": -123343000.0,
        "operating_income": -153291000.0,
        "stockholders_equity": 305259000.0,
        "total_assets": 332645000.0,
        "total_liabilities": 27386000.0
      },
      "period_end": "2025-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.08971398058697697,
        "roa_avg2y": -0.5500314471981591,
        "roa_period_end": -0.43510348870417415,
        "roe_avg2y": -0.6158621687403196,
        "roe_period_end": -0.4741383546431063
      }
    },
    {
      "accn": "0001193125-26-086645",
      "filed": "2026-03-03",
      "fiscal_year": 2024,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 157000.0,
        "cash": 77391000.0,
        "eps_diluted": -4.43,
        "free_cash_flow": -167804000.0,
        "net_income": -301743000.0,
        "operating_cash_flow": -167647000.0,
        "operating_income": -314731000.0,
        "stockholders_equity": 164765000.0,
        "total_assets": 193634000.0,
        "total_liabilities": 28869000.0
      },
      "period_end": "2024-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.1752131824113131,
        "roa_avg2y": -0.8486797695925118,
        "roa_period_end": -1.558316204798744,
        "roe_avg2y": -1.0088415689145884,
        "roe_period_end": -1.8313537462446512
      }
    },
    {
      "accn": "0001193125-26-086645",
      "filed": "2026-03-03",
      "fiscal_year": 2023,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 1241000.0,
        "cash": 170201000.0,
        "eps_diluted": 0.7,
        "free_cash_flow": 10678000.0,
        "net_income": 49271000.0,
        "operating_cash_flow": 11919000.0,
        "operating_income": 38802000.0,
        "stockholders_equity": 433432000.0,
        "total_assets": 517454000.0,
        "total_liabilities": 84022000.0
      },
      "period_end": "2023-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.1938527842891157,
        "roa_avg2y": 0.10841813298830354,
        "roa_period_end": 0.0952181256691416,
        "roe_avg2y": 0.12730883069199356,
        "roe_period_end": 0.11367642444489562
      }
    },
    {
      "accn": "0000950170-25-031309",
      "filed": "2025-03-04",
      "fiscal_year": 2022,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 2526000.0,
        "cash": 62526000.0,
        "eps_diluted": -3.39,
        "free_cash_flow": -182397000.0,
        "net_income": -198375000.0,
        "operating_cash_flow": -179871000.0,
        "operating_income": -201341000.0,
        "stockholders_equity": 340607000.0,
        "total_assets": 391453000.0,
        "total_liabilities": 50846000.0
      },
      "period_end": "2022-12-31",
      "ratio_units": {
        "leverage": "ratio",
        "roa_avg2y": "ratio",
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio",
        "roe_period_end": "ratio"
      },
      "ratios": {
        "leverage": 0.1492805491372755,
        "roa_avg2y": -0.7981821364121939,
        "roa_period_end": -0.5067658186295673,
        "roe_avg2y": -2.094341714219353,
        "roe_period_end": -0.5824160983185901
      }
    },
    {
      "accn": "0000950170-24-018447",
      "filed": "2024-02-22",
      "fiscal_year": 2021,
      "form": "10-K",
      "fundamental_units": {
        "capex": "USD",
        "cash": "USD",
        "eps_diluted": "USD/shares",
        "free_cash_flow": "USD",
        "net_income": "USD",
        "operating_cash_flow": "USD",
        "operating_income": "USD",
        "stockholders_equity": "USD",
        "total_assets": "USD",
        "total_liabilities": "USD"
      },
      "fundamentals": {
        "capex": 353000.0,
        "cash": 50191000.0,
        "eps_diluted": -13.35,
        "free_cash_flow": -75152000.0,
        "net_income": -87931000.0,
        "operating_cash_flow": -74799000.0,
        "operating_income": -82688000.0,
        "stockholders_equity": -151168000.0,
        "total_assets": 105614000.0,
        "total_liabilities": 17431000.0
      },
      "period_end": "2021-12-31",
      "ratio_units": {
        "roa_period_end": "ratio",
        "roe_avg2y": "ratio"
      },
      "ratios": {
        "roa_period_end": -0.832569545704168,
        "roe_avg2y": 0.8071025686919726
      }
    },
    {
      "accn": "0000950170-24-018447",
      "filed": "2024-02-22",
      "fiscal_year": 2020,
      "form": "10-K",
      "fundamental_units": {
        "stockholders_equity": "USD"
      },
      "fundamentals": {
        "stockholders_equity": -66725000.0
      },
      "period_end": "2020-12-31",
      "ratios": {}
    }
  ],
  "latest_filing": {
    "accn": "0001193125-26-086645",
    "filed": "2026-03-03",
    "form": "10-K"
  },
  "note": "Static grepcent export of verified SEC companyfacts-derived values. Monetary values are raw reported units from grepcent's resolved facts; no scaling and no FX conversion. Capex, dividends, and buybacks are reported as positive outflow magnitudes. ROE/ROA include both period-end basis (site-consistent) and average-of-two-years basis where the prior-year denominator exists.",
  "schema_version": "1",
  "sic": "2834",
  "sic_description": "Pharmaceutical Preparations",
  "source_urls": {
    "sec_companyfacts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001658551.json",
    "sec_submissions": "https://data.sec.gov/submissions/CIK0001658551.json"
  },
  "ticker": "AMLX"
}